Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study (opcemisa) of the Combination of ISA101b and Cemiplimab Versus Cemiplimab for Recurrent/metastatic (R/M) HPV16-positive Oropharyngeal Cancer (OPC).
JOURNAL OF CLINICAL ONCOLOGY(2024)
AI 理解论文
溯源树
样例

生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要